Your Health, We Care
Release date: 2026-01-15 16:36:59 Article From: Lucius Laos Recommended: 135
Pralsetinib is indicated for the treatment of patients with advanced or metastatic (spread) medullary thyroid carcinoma (MTC) whose tumors harbor abnormal RET genes (RET-mutant type).
Currently, Pralsetinib manufactured by Lucius Pharmaceuticals is available in only one specification: each capsule contains 100 mg, with 120 capsules per box. This specification is suitable for a full treatment cycle, facilitating patients to take the medication continuously as prescribed by physicians. The specific price of the drug may fluctuate depending on factors such as the purchasing region, medical insurance policies, procurement channels and market conditions.
If you wish to learn about real-time prices, purchasing procedures or relevant preferential policies, please scan the QR code provided on the company official website to contact our professional customer service team directly for detailed consultation. We will provide you with one-on-one answers and service support.
1. Pralsetinib should be stored at room temperature, between 68°F and 77°F (20°C and 25°C). For short periods of time, such as during transportation, it can be exposed to temperatures ranging from 59°F to 86°F (15°C to 30°C).
2. Store the medication in a tightly sealed container at room temperature, away from heat sources, moisture and direct sunlight. Do not freeze.
3. Keep it out of the reach of children.
4. Do not retain expired or unused medications.
5. Consult your doctor about the proper disposal of any unused medication.
6. Overdose and Missed Dose of Pralsetinib
1. If you or someone else has taken an overdose of Pralsetinib, seek medical attention immediately.
2. What should I do if I miss a dose of Pralsetinib?
3. If you miss a dose, take the missed dose as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and take only the next scheduled dose. Do not take a double dose or an extra dose.
4. If you vomit after taking the medication, do not take an additional dose. Instead, take the next dose at the regular scheduled time.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：3012025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
